MedTrace Logo

Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis

NCT00012467 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2009-06-03

No results posted yet for this study

Summary

The purpose of this study is to examine the antifungal activity of recombinant interferon-gamma 1b (rIFN-gamma 1b) given with standard antifungal therapy.

Conditions

  • Meningitis, Cryptococcal
  • HIV Infections

Interventions

DRUG

Itraconazole

DRUG

Flucytosine

DRUG

Fluconazole

DRUG

Amphotericin B

DRUG

Interferon gamma-1b

Sponsors & Collaborators

  • InterMune

    lead INDUSTRY

Study Design

Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-01-31
Completion
2001-07-31

Countries

  • United States
  • Peru

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00012467 on ClinicalTrials.gov